



# Sodium Valproate Oral Solution

*IIP-EU-Development Line*  
Therapeutic indication: Epilepsy




## Oral Solution 300 mg/ml:

One ml of the oral solution contains:  
300 mg sodium valproate



We expressly point out that these dossiers or marketing authorisations cannot be used in countries where corresponding medicinal products or the application of such products are protected by patent.

## Prescriptions of Antiepileptics (German Market)



Source: Schwabe, Paffrath Arzneiverordnungsreport

### Product Advantages: High Quality IIP-EU-Development Line

- Dossier for 300 mg/ml available
- cGMP compliant, European API manufacturer
- cGMP compliant, European contract manufacturer with high manufacturing capacities for sale peaks
- Competitive prices, high batch sizes
- Stability data for industrial scale batches available
- Inert glass bottles
- Oral Solution, solution for injection, gastro-resistant tablets and sodium valproate/valproic acid prolonged-release film-coated tablets ⇒ Complete package for Sodium Valproate /Valproic acid available
- Exposé with scientific data available upon request



#### IIP – Institut für industrielle Pharmazie Forschungs- und Entwicklungsgesellschaft mbH

Management  
Benzstraße 2a  
63741 Aschaffenburg, Germany  
Tel.: 00 49 - (0) 60 21-5 85 93 - 0  
Fax: 00 49 - (0) 60 21-5 85 93 - 28  
E-Mail: management@iip.de  
www.iip.de

Regulatory affairs – Technical department  
Benzstraße 2a  
63741 Aschaffenburg, Germany  
Tel.: 00 49 - (0) 60 21-5 85 93 - 0  
Fax: 00 49 - (0) 60 21-5 85 93 - 28  
E-Mail: regaffairs@iip.de  
www.iip.de